- Organizations: Ollin Biosciences
Business
Johnson & Johnson to acquire Ollin Biosciences in deal worth up to $3.3B
Pending transaction includes phase 3 funding for OLN324, an investigational bispecific antibody under evaluation for wet AMD and DME.Pipeline
Ollin raises $330M to advance OLN324 in phase 3 studies for DME and wet AMD
Financing to support global clinical development of its bispecific antibody programs following promising phase 1b data readout in a head-to-head against faricimab.Business